This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (43)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Infectious Diseases, Other  • Endophthalmitis  • Drug Therapy  • Adverse Effects  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Intravitreal injections of triamcinolone acetonide have recently been used as treatment for various intraocular, neovascular, proliferative, or edematous diseases, such as diffuse diabetic macular edema, proliferative diabetic retinopathy, proliferative vitreoretinopathy, chronic prephthisical ocular hypotony, chronic uveitis, and persistent pseudophakic cystoid macular edema.^1-4 In view of the enlarging therapeutic spectrum of use for intravitreal triamcinolone acetonide, the purpose of the present study was to evaluate the frequency of infectious endophthalmitis or sterile intraocular inflammation after the injection.^5-6

The clinical interventional study included 454 eyes that received intravitreal injection of 25 mg of triamcinolone acetonide as treatment for diffuse diabetic macular edema (n = 68), exudative age-related macular degeneration (n = 211), retinal vein occlusion (n = 28), chronic prephthisical ocular hypotony (n = 4), chronic uveitis (n = 7), and persistent pseudophakic cystoid macular edema (n = 9); in combination with retinal exocryocoagulation as treatment for neovascular secondary angle-closure glaucoma (n . . . [Full Text of this Article]

Jost B. Jonas, MD; Ingrid Kreissig, MD; Robert F. Degenring, MD
Mannheim, Germany

Corresponding author: Jost B. Jonas, MD, Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany (e-mail: Jost.Jonas@augen.ma.uni-heidelberg.de).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide
Jonisch et al.
Br J Ophthalmol 2008;92:1051-1054.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)
Paccola et al.
Br J Ophthalmol 2008;92:76-80.
ABSTRACT | FULL TEXT  

Effects of intravitreal triamcinolone acetonide injection with and without preservative
Maia et al.
Br J Ophthalmol 2007;91:1122-1124.
ABSTRACT | FULL TEXT  

Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study
Brasil et al.
Br J Ophthalmol 2007;91:761-765.
ABSTRACT | FULL TEXT  

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye
Kosobucki et al.
Br J Ophthalmol 2006;90:705-708.
ABSTRACT | FULL TEXT  

Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema: A Randomized Clinical Trial
Bonini-Filho et al.
IOVS 2005;46:3845-3849.
ABSTRACT | FULL TEXT  

Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2005;123:1338-1343.
ABSTRACT | FULL TEXT  

Acute Endophthalmitis Incidence: Intravitreal Triamcinolone
Westfall et al.
Arch Ophthalmol 2005;123:1075-1077.
ABSTRACT | FULL TEXT  

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
Spandau et al.
Br J Ophthalmol 2005;89:999-1003.
ABSTRACT | FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Macular Edema--Reply
Jonas et al.
Arch Ophthalmol 2004;122:1086-1088.
FULL TEXT